LU92326I2 - Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) - Google Patents

Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)

Info

Publication number: LU92326I2
Authority: LU; Luxembourg
Prior art keywords: ilaris; canakinumab; pharmaceutically acceptable; acceptable derivatives; derivatives
Prior art date: 2005-10-26

Application number

LU92326C

Other languages

English (en)

Other versions

LU92326I9 (fr

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2013-12-05

Publication date

2014-02-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92326(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-05 Application filed by Novartis Ag filed Critical Novartis Ag

2014-02-05 Publication of LU92326I2 publication Critical patent/LU92326I2/fr

2019-01-16 Publication of LU92326I9 publication Critical patent/LU92326I9/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Zoology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)

LU92326C 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) LU92326I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73043505P	2005-10-26	2005-10-26
US74212505P	2005-12-02	2005-12-02
PCT/US2006/041479 WO2007050607A2 (fr)	2005-10-26	2006-10-24	Nouvelle utilisation de composes il-1beta

Publications (2)

Publication Number	Publication Date
LU92326I2 true LU92326I2 (fr)	2014-02-05
LU92326I9 LU92326I9 (fr)	2019-01-16

Family

ID=37806690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92326C LU92326I2 (fr)	2005-10-26	2013-12-05	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU00078C LUC00078I2 (fr)	2005-10-26	2018-06-11	Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00078C LUC00078I2 (fr)	2005-10-26	2018-06-11	Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Country Status (28)

Country	Link
US (9)	US8105587B2 (fr)
EP (5)	EP2848258B1 (fr)
JP (4)	JP2009513645A (fr)
KR (3)	KR101749388B1 (fr)
CN (2)	CN102861332A (fr)
AU (1)	AU2006306280B2 (fr)
BR (1)	BRPI0617830B8 (fr)
CA (3)	CA2963828A1 (fr)
CY (4)	CY1113378T1 (fr)
DK (2)	DK2848258T3 (fr)
ES (3)	ES2944067T3 (fr)
HU (2)	HUE036973T2 (fr)
IL (4)	IL190545A (fr)
JO (2)	JO2826B1 (fr)
LT (3)	LT2848258T (fr)
LU (2)	LU92326I2 (fr)
MA (1)	MA29919B1 (fr)
NO (2)	NO345888B1 (fr)
NZ (1)	NZ567222A (fr)
PH (2)	PH12013501287B1 (fr)
PL (2)	PL2848258T3 (fr)
PT (2)	PT2848258T (fr)
RU (2)	RU2468817C2 (fr)
SI (2)	SI2848258T1 (fr)
TN (1)	TNSN08189A1 (fr)
TR (1)	TR201802449T4 (fr)
TW (3)	TWI388335B (fr)
WO (1)	WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2963828A1 (fr)	2005-10-26	2007-05-03	Novartis Ag	Nouvelle utilisation de composes il-1beta
AU2012203931B2 (en) *	2007-05-29	2014-04-24	Novartis Ag	New indications for anti-IL-I-beta therapy
WO2008145664A1 (fr) *	2007-05-29	2008-12-04	Novartis Ag	Nouvelles indications pour une thérapie anti-il-i-bêta
HRP20130042T1 (hr) *	2008-06-06	2013-03-31	Xoma Technology Ltd.	Postupci lijeäśenja reumatoidnog artritisa
EP2196476A1 (fr)	2008-12-10	2010-06-16	Novartis Ag	Formulation d'anticorps
US8911722B2 (en)	2009-09-14	2014-12-16	The Regents Of The University Of Colorado, A Body Corporate	Modulation of yeast-based immunotherapy products and responses
AU2010306681A1 (en) *	2009-10-15	2012-04-19	Abbvie Inc.	IL-1 binding proteins
TWI500427B (zh) *	2010-05-14	2015-09-21	Abbvie Inc	Ｉｌ－１結合蛋白
MX2013007332A (es) *	2010-12-21	2014-01-23	Abbvie Inc	Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
CA3295783A1 (en)	2011-05-10	2026-03-02	Prometheus Laboratories, Inc.	Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (fr)	2016-03-10	2017-09-14	Novartis Ag	Arn messager chimiquement modifié
KR20200009095A (ko)	2017-05-31	2020-01-29	프로메테우스 바이오사이언시즈, 인크.	크론병 환자에서 점막 치유를 평가하는 방법
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018234879A1 (fr)	2017-06-22	2018-12-27	Novartis Ag	UTILISATION D'ANTICORPS DE LIAISON IL-1β DANS LE TRAITEMENT DU CANCER
JP2021523894A (ja)	2018-05-09	2021-09-09	ノバルティスアーゲー	カナキヌマブの使用
US20220056123A1 (en)	2018-12-21	2022-02-24	Novartis Ag	Use of il-1beta binding antibodies
US20220025036A1 (en)	2018-12-21	2022-01-27	Novartis Ag	Use of il-1beta binding antibodies
WO2020128637A1 (fr)	2018-12-21	2020-06-25	Novartis Ag	UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
JP2022516850A (ja)	2018-12-21	2022-03-03	ノバルティスアーゲー	骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用
TWI793503B (zh)	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
KR20230109107A (ko) *	2022-01-10	2023-07-19	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP1690935A3 (fr)	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
WO1995001997A1 (fr) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
WO1995016353A1 (fr)	1993-12-14	1995-06-22	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Traitement systemique par genes des affections des tissus conjonctifs
WO1998002441A2 (fr)	1996-07-12	1998-01-22	Ariad Pharmaceuticals, Inc.	Elements et procedes pour traiter ou prevenir les mycoses pathogènes
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
AU778975B2 (en)	1999-02-10	2004-12-23	Interleukin Genetics, Inc.	Therapeutics and diagnostics based on an IL-1B mutation
PT1210320E (pt) *	1999-07-16	2005-01-31	Leo Pharma As	Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
IL147803A0 (en)	1999-08-24	2002-08-14	Ariad Gene Therapeutics Inc	28-epirapalogs
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
EP1282435A2 (fr)	2000-05-12	2003-02-12	Immunex Corporation	Inhibiteurs d'interleukine 1 dans le traitement de maladies
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
CN1253449C (zh)	2000-11-07	2006-04-26	诺瓦提斯公司	作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
US20050075488A1 (en) *	2001-07-26	2005-04-07	Bright Stuart Willis	Interleukin-1 beta antibodies
US20030049255A1 (en)	2001-08-07	2003-03-13	Sims John E.	Interleukin-1 receptors in the treatment of diseases
ATE556482T1 (de)	2001-12-01	2012-05-15	Iskra Wind Turbines Ltd	Synchron-wechselstromgenerator mit einem bremsmechanismus
KR200268109Y1 (ko)	2001-12-06	2002-03-15	김정훈	편평형 무정류자 진동모터
EP1478648B1 (fr)	2002-02-01	2014-04-30	ARIAD Pharmaceuticals, Inc.	Composes contenant du phosphore et utilisations associees
MXPA04007124A (es)	2002-02-01	2004-10-29	Omeros Corp	Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
EP1487465A4 (fr)	2002-02-11	2007-05-30	Arkion Life Sciences Llc	Facteur inhibiteur des cytokines purifie
AR039209A1 (es)	2002-04-03	2005-02-09	Novartis Ag	Derivados de indolilmaleimida
KR20050084224A (ko)	2002-12-09	2005-08-26	더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	야누스 티로신 키나제 3을 선택적으로 저해하는 방법
JP4538461B2 (ja) *	2003-01-24	2010-09-08	アプライドモレキュラーエボリューション，インコーポレイテッド	ヒトＩＬ−１βアンタゴニスト
GB0303337D0 (en) *	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
WO2005047906A1 (fr)	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methodes de controle de l'il-18
ES2389203T3 (es)	2004-01-12	2012-10-24	Ym Biosciences Australia Pty Ltd	Inhibidores de quinasa selectivos
DK1720893T3 (en)	2004-02-26	2014-11-24	Baylor Res Inst	COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
CN1980658A (zh)	2004-05-27	2007-06-13	沃泰克斯药物股份有限公司	治疗自身炎性疾病的ice抑制剂
US7459426B2 (en) *	2004-06-04	2008-12-02	Regeneron Pharmaceuticals, Inc.	Methods of using IL-1 antagonists to treat autoinflammatory disease
EP1883427A4 (fr)	2005-01-20	2010-04-21	Univ Rochester	Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
AU2006227165B2 (en)	2005-03-18	2011-11-10	Microbia, Inc.	Production of carotenoids in oleaginous yeast and fungi
ES2335232T3 (es)	2005-06-21	2010-03-23	Xoma Technology Ltd.	Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CA2963828A1 (fr)	2005-10-26	2007-05-03	Novartis Ag	Nouvelle utilisation de composes il-1beta

2006
- 2006-10-24 CA CA2963828A patent/CA2963828A1/fr not_active Abandoned
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en not_active IP Right Cessation
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active Active
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/en active
- 2006-10-24 CA CA2626214A patent/CA2626214C/fr active Active
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/fr not_active Ceased
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Ceased
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 CA CA2898369A patent/CA2898369C/fr active Active
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/fr active Active
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 EP EP06826560A patent/EP1940465B1/fr active Active
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/fr active Pending
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/fr active Active
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active Active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 EP EP10181100A patent/EP2332577A1/fr not_active Withdrawn
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287B1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I2/el unknown
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
2015
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
2018
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I1/el unknown
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en not_active Abandoned
2025
- 2025-05-23 US US19/217,696 patent/US20260125463A1/en active Pending

Also Published As

Publication number	Publication date
EP2848258A1 (fr)	2015-03-18
PH12013501287A1 (en)	2016-02-01
IL245387B (en)	2019-09-26
PH12020500559A1 (en)	2021-06-14
LT2848258T (lt)	2018-02-26
KR101518064B1 (ko)	2015-05-06
ES2389110T3 (es)	2012-10-23
HK1121041A1 (en)	2009-04-17
CN101291693B (zh)	2012-10-03
IL258983B (en)	2020-10-29
IL245387A0 (en)	2016-06-30
JO2826B1 (en)	2014-09-15
MA29919B1 (fr)	2008-11-03
JP2017206552A (ja)	2017-11-24
CA2626214A1 (fr)	2007-05-03
RU2008120625A (ru)	2010-01-20
US20260125463A1 (en)	2026-05-07
EP1940465A2 (fr)	2008-07-09
PT2848258T (pt)	2018-03-20
SI2848258T1 (en)	2018-03-30
TNSN08189A1 (en)	2009-10-30
AU2006306280B2 (en)	2010-06-17
IL190545A0 (en)	2008-11-03
NO345140B1 (no)	2020-10-12
US9649377B2 (en)	2017-05-16
LTPA2018506I1 (lt)	2018-06-25
ES2662420T3 (es)	2018-04-06
LTC2848258I2 (lt)	2019-08-12
CY2018018I2 (el)	2018-12-12
PL2848258T3 (pl)	2018-06-29
JP6286403B2 (ja)	2018-02-28
US20170218063A1 (en)	2017-08-03
JP6061747B2 (ja)	2017-01-18
EP3332807B1 (fr)	2023-02-22
CA2898369C (fr)	2017-06-20
IL258983A (en)	2018-06-28
US20120039910A1 (en)	2012-02-16
US8409576B2 (en)	2013-04-02
CY2018018I1 (el)	2018-12-12
TR201802449T4 (tr)	2018-03-21
US8105587B2 (en)	2012-01-31
CN102861332A (zh)	2013-01-09
PT1940465E (pt)	2012-10-03
BRPI0617830A2 (pt)	2011-08-09
JOP20140120B1 (ar)	2021-08-17
EP3332807A3 (fr)	2018-06-20
IL190545A (en)	2016-09-29
JP2013166757A (ja)	2013-08-29
AU2006306280A1 (en)	2007-05-03
HUS1800025I1 (hu)	2018-07-30
CA2898369A1 (fr)	2007-05-03
DK2848258T3 (en)	2018-03-19
RU2012133522A (ru)	2014-02-20
KR20170038131A (ko)	2017-04-05
US20240083997A1 (en)	2024-03-14
TWI388335B (zh)	2013-03-11
PH12013501287B1 (en)	2016-02-01
CY1113378T1 (el)	2015-11-04
NO20200810A1 (no)	2008-07-22
LU92326I9 (fr)	2019-01-16
BRPI0617830B8 (pt)	2021-05-25
US20180201674A1 (en)	2018-07-19
CN101291693A (zh)	2008-10-22
LUC00078I2 (fr)	2018-08-14
NZ567222A (en)	2011-07-29
TW200803898A (en)	2008-01-16
CY2013046I1 (el)	2015-11-04
KR20150013834A (ko)	2015-02-05
CA2626214C (fr)	2016-06-21
WO2007050607A3 (fr)	2007-06-28
EP2848258B1 (fr)	2017-12-13
US20130171167A1 (en)	2013-07-04
IL277406A (en)	2020-11-30
WO2007050607A2 (fr)	2007-05-03
DK1940465T3 (da)	2012-10-22
ES2944067T3 (es)	2023-06-19
KR101749388B1 (ko)	2017-06-20
JP2009513645A (ja)	2009-04-02
SI1940465T1 (sl)	2012-10-30
NO345888B1 (no)	2021-09-27
EP4218815A2 (fr)	2023-08-02
HK1204767A1 (en)	2015-12-04
US20080286266A1 (en)	2008-11-20
CY2013046I2 (el)	2015-11-04
TW201617097A (zh)	2016-05-16
TW201302220A (zh)	2013-01-16
EP4218815A3 (fr)	2024-03-27
EP2332577A1 (fr)	2011-06-15
US20210147533A1 (en)	2021-05-20
RU2571563C2 (ru)	2015-12-20
CA2963828A1 (fr)	2007-05-03
KR20080059598A (ko)	2008-06-30
NO20082344L (no)	2008-07-22
HUE036973T2 (hu)	2018-08-28
HK1252316A1 (en)	2019-05-24
BRPI0617830B1 (pt)	2020-10-20
CY1120018T1 (el)	2018-12-12
EP1940465B1 (fr)	2012-08-01
TWI626056B (zh)	2018-06-11
LTC1940465I2 (lt)	2017-12-11
RU2468817C2 (ru)	2012-12-10
TWI537003B (zh)	2016-06-11
US20150322148A1 (en)	2015-11-12
JP2016020377A (ja)	2016-02-04
PL1940465T3 (pl)	2013-01-31
EP3332807A2 (fr)	2018-06-13

Publication	Publication Date	Title
LU93189I2 (fr)	2016-10-31	Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU93093I2 (fr)	2016-08-01	Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU93096I2 (fr)	2016-08-01	Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92871I2 (fr)	2016-01-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LUC00127I2 (fr)	2020-10-06	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92336I2 (fr)	2014-02-17	Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92419I2 (fr)	2014-06-02	Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
BE2014C011I2 (fr)	2026-01-14	Administration d'inhibiteurs de dipeptidyl peptidase
LTPA2016032I1 (lt)	2016-12-12	Hipoglikeminių agentų skyrimo būdai
LU91882I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
PL1954684T3 (pl)	2014-10-31	Związek oksazolowy i kompozycja farmaceutyczna
EP1718667A4 (fr)	2009-04-08	Liants et conjugues heterocycliques auto-immolateurs
HRP20160880T1 (hr)	2016-09-23	Formulacija obložene tablete i postupak
EP1594979A4 (fr)	2006-12-20	Surfaces modifiees par des nanocylindres
LU91883I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
ATE337793T1 (de)	2006-09-15	Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
LU91624I2 (fr)	2010-01-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU92634I2 (fr)	2015-11-02	Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
DE602005008726D1 (de)	2008-09-18	Verwendet
EP1951050A4 (fr)	2011-04-27	Compositions therapeutiques et procedes
NL1024677A1 (nl)	2004-05-06	Therapeutische prolinederivaten.
BRPI0611025A2 (pt)	2016-11-16	composto, uso de um composto, e, composição farmacêuticamente aceitável